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ResistinAbstract Background: Obstructive sleep apnea (OSA) has been independently associated with
cardiovascular diseases, including hypertension, coronary heart disease and heart failure. Also, it
had a deleterious impact on renal function and a link to diabetes mellitus (DM) and insulin
resistance. Resistin is new adipokine and may play a role in cardiac, diabetics and renal patients.
Aim of the work: The aim of this work is screening of cardiac dysfunction, DM and renal
impairment in OSA patients and to study the role of resistin serum level in occurrence of these
complications.
Subjects and methods: This study was carried out on 10 control persons (group I) and 143
patients with OSA (group II). The following were done to all persons: body mass index (BMI),
blood pressure measurement, fasting and post prandial blood sugar levels, serum creatinine and
ECG, diagnostic sleep study, echocardiogram, estimated glomerular ﬁltration rate (eGFR) and
serum resistin assay. According to the above results, group II was divided into 4 subgroups, A
(33OSAS patients), B (21 OSAS patients with cardiac troubles), C (40 OSAS patients with DM)
and D (13 OSAS patients with renal impairment). 36 OSAS patients were excluded from the study
because they had either 2 or more of the above abnormalities (cardiac, DM and renal).
Results: There was signiﬁcant increase of ESS and plasma resistin level in subgroups IIB, IIC
and IID as compared group I and subgroup IIA which was signiﬁcantly increased as compared
to group I. There was no signiﬁcant difference of BMI in subgroups IIA, IIB, IIC and IID but
SaO2 and AHI were signiﬁcantly increased in subgroups IIB, IIC and IID as compared to IIA.
In group II, there was a signiﬁcant positive correlation between plasma resistin level and AHI,
SaO2 but there was no signiﬁcant correlation between BMI and plasma resistin level.d.
130 B.I. El-Shafey et al.Conclusion: OSA patients can be complicated with cardiac diseases, DM and renal impairment
through elevated resistin serum levels.
Recommendation: Effect of CPAP on resistin serum level must be evaluated in these patients.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Obstructive sleep apnea (OSA) is a growing problem in the
United States with important negative health implications.
In addition to substantial morbidity as evidenced by
increased health services utilization [1], reduced functional
capabilities and lower quality of life [2], OSA has also been
associated with increased mortality [3]. OSA has been inde-
pendently associated with cardiovascular diseases, including
hypertension [4], coronary heart disease, heart failure, and
stroke [5]. Several mechanisms have been proposed to
explain this excess cardiovascular risk among individuals
with OSA, including hypoxemia-induced endothelial dys-
function, accelerated atherosclerosis, and altered cardiovas-
cular hemodynamics. Each of these factors can have a
deleterious impact on renal function so, there is a link
between OSA and chronic kidney disease (CKD). Although
data are limited, OSA appears to alter renal hemodynamics
and function in a harmful manner [6]. Cross-sectional results
from the Sleep Heart Health Study have shown a signiﬁcant
association between obstructive sleep apnea and chronic
heart failure [7]. The prevalence of obstructive sleep apnea
in a population with chronic heart failure has been shown
to be as high as 30–40% [8,9]. Comorbidities, accompanying
obstructive sleep apnea such as systemic hypertension and
obesity [10], are also associated with the development of
chronic heart failure [11]. Ciccone et al. have established
that the severity and duration of obstructive sleep apnea
are independent contributors for early atherosclerotic
lesions, as assessed by the intima media thickness [12].
Moreover emerging data suggest that obstructive sleep apnea
is not only associated with, but also contributes to the
progression of cardiac remodeling in heart failure through
different mechanisms. Also, OSA has a link to diabetes
mellitus (DM) and insulin resistance as conﬁrmed by Lp
et al. (2002) who found that OSA subjects were more insulin
resistant as indicated by their higher levels of serum insulin
and insulin resistance index and concluded that apnea-hypo-
pnea index (AHI) and minimum oxygen saturation attained
during sleep are independent determinants of insulin resis-
tance [13]. Resistin is an adipocyte-derived cytokine
(adipokine) that may contribute to the development of
obesity [14–16], insulin resistance [17,18] and the metabolic
syndrome. More recent studies have shown the causative
association between resistin and systemic inﬂammation
[19,20], especially in the vascular endothelium [21]. From
the viewpoint of inﬂammation, it is notable that plasma res-
istin concentrations increase with increasing inﬂammatory
mediator levels predicting the severity of coronary athero-
sclerosis [22] also, Axelsson et al. (2006) concluded that
the serum level of resistin was higher in patients with
CKD [23].Aim of the work
The aim of this work is screening of cardiac dysfunction, DM
and renal impairment in OSA patients and to study the role of
resistin serum level in occurrence of these complication.
Subjects and methods
This study was carried out on 143 patients with OSAS and 10
control persons in the period from January 2011 to April 2014
in Chest Department – Tanta University Hospital. Epworth
Sleepiness Scale (ESS) was done to 2500 persons (non-smok-
ers, not known to be cardiac, diabetic or renal patients). 152
persons had ESS 11 or more (9 refused to complete the study),
2348 persons had ESS > 9 (10 of them was considered as con-
trol group). All persons included in this study were divided
into 2 groups, group I (10 control persons, their mean age
was 53.2 ± 1.9 years) and group II (143 persons suspected to
be OSAS patients, their mean age was 57.4 ± 2.8 years). The
following were done to all persons:
Body mass index (BMI)
Blood pressure measurement (2 times/day for 3 successive
days), fasting and post prandial blood sugar levels (patients
were considered diabetics if FPG or PPG levels were P126
andP200 mg/dl), serum creatinine and ECG (Resting electro-
cardiogram was performed to detect the cardiac rhythm, pres-
ence or absence of arrhythmias and the presence of ischemia or
chamber enlargement).
Diagnostic sleep study
It was conducted in the sleep laboratory unit, chest depart-
ment, Tanta university hospital for at least 6 h and started at
10 pm using ResMed ApneaLink Plus system which has
the following components:
a- ApneaLink Plus device recorder which registers patient’s
respirations with the nasal pressure cannula.
b- Effort sensor measures the respiratory effort.
c- Thoraco-abdominal belt.
d- Nasal cannula (Res Med soft cannula no. 70388).
e- Pulse oximeter with ﬁnger pulse sensor measuring the
blood oxygen saturation and pulse rate.
f- USB cable.
g- Computer with ApneaLink Plus software installed.Echocardiogram
Transthoracic two-dimensional (2D) echocardiography was
performed using digital commercial harmonic imaging
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Figure 2 Correlation between plasma resistin level and AHI in
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Figure 3 Correlation between plasma resistin level and BMI in
group II.
Serum resistin level in sleep apnea patients 131ultrasound systems equipped with a S3 3 MHz phased-array
transducer (Vivid 7, General Electrics Healthcare Systems,
USA) with the patient in the left-lateral decubitus position
and a raised left arm. Images were adjusted for depth, focus
position, frame rate and sector size for an optimal display of
the structure of interest. Images were displayed on the echocar-
diographic system and measurements were obtained from
recordings in the parasternal LAX acoustic window directly
from the 2D images. End-diastolic and end-systolic frames
were identiﬁed visually by frames with the greatest and the
smallest LV cavity. Dimensions were measured in the LV
minor axis plane at the mitral chordae level at the tips of the
papillary muscles. LVIDd and LVIDs, respectively and wall
thicknesses (anteroseptal–IVSd and inferolateral–LVPWd)
were measured at end-diastole(d) and end-systole(s), respec-
tively, and were averaged over three consecutive heart cycles
[24].
Estimated glomerular ﬁltration rate (EGFR): Modiﬁcation of
diet in renal disease (MDRD) equation
GFR (mL/min/1.73 m2)= 186 · (Scr · 0.0113)  1.154 · (age)
 0.203 · (0.742 if female) [25]. The GFRP 90 mL/min/
1.73 m2 is considered to be normal if there is no clinical man-
ifestation of renal disease [26].
Serum resistin assay
After sleep study between 8:00 am and 9:00 am on the morn-
ing, venous blood sample was obtained in the fasting state to
measure resistin plasma level using performed commercially
available assays or routine methods (Kit from LINCO
Research, St Charles, MS) [23].
According to above results, group II was divided into 4
subgroups, A (33OSAS patients), B (21 OSAS patients with
cardiac troubles), C (40 OSAS patients with DM) and D (I3
OSAS patients with renal impairment). 36 OSAS patients were
excluded from the study because they had either 2 or more of
the above abnormalities (cardiac, DM and renal).
Results
There was signiﬁcant increase of ESS and plasma resistin level
in subgroups IIB, IIC and IID as compared group I and sub-
group IIA which was signiﬁcantly increased as compared to
group I. There was no signiﬁcant difference of BMI in sub-Figure 1 Percent of patients in subgroups A, B, C and D.groups IIA, IIB, IIC and IID but SaO2 and AHI were signif-
icantly increased in subgroups IIB, IIC and IID as compared
to IIA. In group II, there was a signiﬁcant positive correlation
between plasma resistin level and AHI, SaO2 but there was no
signiﬁcant correlation between BMI and plasma resistin level
(Figs 1–4, Tables 1–10).
Discussion
Obstructive sleep apnea (OSA) is closely related to systemic
inﬂammation [27]. A wide variety of pro-inﬂammatory media-
tors are elevated in the circulation of patients with OSA
[28,29]. Additionally, OSA patients have peripheral leukocytes
which can generate larger amounts of cytokines [30,31], adhe-
sion molecules [32] and free radicals [33]. In general however it
is predominantly associated with markers of inﬂammation –
C-reactive protein, tumor necrosis factor-a and interleukin-6,
which are well accepted predictors of heart failure incidence
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Figure 4 Correlation between plasma resistin level and SaO2 in
group II.
Table 1 Number and percent of patients in subgroups A, B, C
and D.
N (143) Percent
A 33 23
B 21 15
C 40 28
D 13 9
Excluded from the study 36 25
Table 2 Mean and standard deviation of some echocardio-
graphic parameters and blood pressure in subgroup IIB.
Minimum Maximum Mean Std. deviation
LVEDD 53.00 69.00 59.05 5.136
LVESD 35.00 56.00 43.73 6.606
Septal wall thickness 11.00 16.00 14.57 1.804
Posterior wall thickness 11.00 15.00 13.47 1.576
Blood pressure systolic 150.00 200.00 175.78 14.362
Blood pressure diastolic 100.00 120.00 107.63 5.619
Table 3 Clinical criteria of subgroup IIB.
Frequency Percent
LL edema +ve 19 90.50
Orthopnea +ve 19 90.50
Chest pain +ve 19 90.50
ECG changes IHD 11 52
IHD+ Sinus tachycardia 4 19
IHD+ Extrasystoles 5 24
IHD+ Supraventricular
tachycardia
1 5
132 B.I. El-Shafey et al.[34,35]. Lehrke et al. concluded that Inﬂammation is a hyper-
resistinemic state in humans, and cytokine induction of resistin
may contribute to insulin resistance in endotoxemia, obesity,and other inﬂammatory states [19]. Bokarewa et al. found that
resistin accumulates in the inﬂamed joints of patients with
rheumatoid arthritis and its levels correlate with other markers
of inﬂammation and displays its potent pro-inﬂammatory
properties by (1) strongly up-regulating IL-6 and TNF-alpha,
(2) responding to TNF-alpha challenge, (3) enhancing its own
activity by a positive feedback, and ﬁnally (4) inducing arthri-
tis when injected into healthy mouse joints. Pro-inﬂammatory
properties of resistin were abrogated by NF-jB inhibitor indi-
cating the importance of NF-kappaB signaling pathway for
resistin-induced inﬂammation and concluded that resistin is a
new and important member of the cytokine family with potent
regulatory functions [20]. Yamamoto et al. found that levels of
resistin and IL-6 were simultaneously elevated in men with
OSA compared with those in men without OSA and tended
to increase with increasing disease severity, which was based
on the apnea-hypopnea index (AHI) and the average oxyhe-
moglobin saturation during sleep. Resistin production can be
enhanced by hypoxic stress during sleep in OSA patients, pos-
sibly mediating systemic inﬂammatory processes [36]. In con-
trast, Ursavas et al. concluded that no signiﬁcant difference
was noted in the levels of resistin in the OSA group when com-
pared to controls and there was also no signiﬁcant correlation
was observed between resistin, and any polysomnographic
parameters [37]. Hung et al. found that hypoxia increases the
resistin expression in cultured rat vascular smooth muscle cells
under hypoxia. The hypoxia-induced resistin is mediated
through reactive oxygen species, ERK mitogen-activated pro-
tein (MAP) kinase and nuclear factor of activating T cells
pathway [38]. Ramar and Caples concluded that vascular
changes related to obstructive sleep apnea (OSA) can lead to
chronic cardiovascular consequences such as hypertension.
The cardiovascular consequences are owing to nocturnal per-
turbations related to intrathoracic pressure changes, intermit-
tent hypoxia, sympathetic neural activation, endothelial
dysfunction, oxidative stress and systemic inﬂammation. Inter-
mittent hypoxia due to sleep-related events in OSA activates
the renin-angiotensin system and increases the levels of endo-
thelin-1. Intermittent hypoxia also results in oxidative stress,
as evidenced by elevated levels of xanthine oxidoreductase,
lipid peroxidation and the presence of reactive oxygen species.
There is also evidence for a decrease in antioxidant capacity.
OSA is a state of inﬂammation as evidenced by elevated levels
of C-reactive protein, IL-6, NF-jB, TNF-a, ICAM-1, VCAM-
1 and E-selectin. This may suggest that OSA is a predisposing
factor for atherogenesis [39]. Cherneva1 et al. found that
serum level of resistin is more in OSA patients with impaired
systolic function as compared to OSA patients with preserved
ejection fraction [40]. Papadopoulos DP found that patients
with masked hypertension have lower adiponectin levels and
higher resistin levels compared with normotensive individuals
[41]. Reilly et al. found that resistin levels were positively asso-
ciated with levels of inﬂammatory markers, including soluble
tumor necrosis factor-alpha receptor-2, interleukin-6, and lipo-
protein-associated phospholipase A2, but not measures of
insulin resistance and also were associated with increasing cor-
onary artery calciﬁcation (CAC) [42]. Pischon concluded that
plasma resistin levels are signiﬁcantly associated with the pres-
ence of CHD in women and this association can largely be
explained by concomitant inﬂammatory processes [43]. Fran-
kel et al. concluded that increased circulating concentrations
of resistin were associated with incident heart failure [44]. Lp
Table 4 Mean and standard deviation of blood glucose level in subgroup IIC.
Minimum Maximum Mean Std. deviation
Fasting serum glucose level 126.00 173.00 149.7179 15.37077
Postprandial serum glucose level 200.00 256.00 224.4359 15.55939
Table 5 Clinical criteria of subgroup IIC.
Frequency Percent
Polyurea +ve 31 77.5
Polydypsia +ve 31 77.5
Table 6 Mean, standard deviation of eGFR in subgroup IID.
Minimum Maximum Mean Std. deviation
eGFR 62.80 84.20 77.746 6.587
Table 7 Clinical criteria of subgroup IID.
Frequency Percent
Puﬀy eye lid +ve 9 69.0
Decreased appetite +ve 12 92.0
Tiredness or fatigue +ve 12 92.0
Mid-back pain +ve 6 46.0
Decreased amount of urine +ve 7 54.0
Maldigestion +ve 9 69.0
Table 10 Correlation between plasma resistin level and AHI,
BMI and SaO2 in group II.
Plasma resistin level
r P
AHI 0.909 0.001
BMI 0.155 0.117
SaO2 0.863 0.001
Serum resistin level in sleep apnea patients 133et al. and Punjabi provide compelling evidence of an indepen-
dent association between OSA and insulin resistance. This
association is present even in non- obese sleep apnea sufferers.Table 8 Mean, standard deviation and statistical analysis of AHI, E
D).
Group A Group B
AHI Range 10.9–25.9 22.4–45.7
Mean ± SD 18.68 ± 4.9 31.15 ± 6.
ESS Range 11–15 11–22
Mean ± SD 12.79 ± 1.20 14.47 ± 3.
SaO2 Range 5.1–14.9 10.3–42.5
Mean + SD 9.55 ± 2.54 29.90 ± 10
BMI Range 25.1–29.3 25.0–34.0
Mean + SD 27.11 ± 1.30 28.59 ± 2.
Plasma resistin level Range 15.7–25.3 23.2–30.6
Mean + SD 18.38 ± 2.62 27.02 ± 2.
Table 9 Mean, standard deviation and statistical analysis of ESS a
Group I Group II A G
ESS Range 0–6 11–15 1
Mean ± SD 1.4 ± 2.27 12.79 ± 1.20 1
Plasma resistin level Range 5.6–8.3 15.7–25.3 2
Mean ± SD 7.12 ± 0.98 18.38 ± 2.62 2These studies involved larger numbers of subjects than previ-
ous studies which failed to show any such association and it
may be that these earlier studies were underpowered to show
such an association [13,7]. Habib concluded that type 2 DM
patients have signiﬁcantly higher resistin levels that are posi-
tively correlated with body fat mass supporting the evidence
that resistin plays an important role in the pathogenesis of
obesity and insulin resistance [45]. Yin et al. have demon-
strated the presence of resistin in saliva of T2DM and non-dia-
betic subjects. Saliva resistin levels of T2DM are signiﬁcantly
higher than those of non-diabetic controls and found that posi-
tive correlation of serum and salivary resistin with BMI and
HOMA-IR existed in T2DM [46]. In contrast, Zhang con-
ﬁrmed that resistin levels were the same in diabetic patients
as compared to control group [47]. Agrawal et al. found that,
in obese adults, increasing severity of OSA is associated with
higher serum creatinine levels but not a greater degree of
albuminuria [48]. Early studies of OSA and renal functionSS, SaO2, BMI and plasma resistin level in group II (A, B, C and
Group C Group D F test P value
21.5–47.2 21.1–45.2 32.202 0.001
27 34.38 ± 8.39 29.22 ± 7.47
11–23 11–24 9.390 0.001
92 17.0 ± 3.83 15.46 ± 4.81
12.7–45.6 12.0–43.8 28.016 0.001
.59 27.45 ± 11.55 22.86 ± 11.46
25.0–33.1 25.2–32.8 1.872 0.139
98 28.01 ± 2.60 27.53 ± 2.24
24.5–31.9 22.5–31.8 99.114 0.001
16 28.34 ± 2.16 26.91 ± 3.19
nd plasma resistin level in groups I and II (A, B, C and D).
roup II B Group II C Group II D F test P value
1–22 11–23 11–24 45.691 0.001
4.47 ± 3.92 17.0 ± 3.83 15.46 ± 4.81
3.2–30.6 24.5–31.9 22.5–31.8 214.864 0.001
7.02 ± 2.16 28.34 ± 2.16 26.91 ± 3.19
134 B.I. El-Shafey et al.demonstrated greater urine protein excretion in the presence of
OSA [49,50] that was shown to improve with surgical correc-
tion of OSA [51]. Cross-sectional studies found weak associa-
tions of proteinuria with arousal index (frequency of arousals
during sleep) [52] and minimal oxygen saturation during sleep
[53]. Presence of proteinuria represents established glomerular
damage [54]. Axelsson found that serum level of resistin was
markedly elevated in the CKD patients with both advanced
and mild to moderate renal function impairment, as compared
to controls and also its level was strongly associated with both
GFR and inﬂammatory biomarkers in CKD. As the signiﬁcant
relationship between plasma resistin levels and insulin resis-
tance was lost following the correction for GFR, resistin is
not a likely mediator of insulin resistance in patients with
CKD. OSA is associated with hypoxemia and sleep fragmenta-
tion, which activates the sympathetic nervous system, the
renin-angiotensin-aldosterone system, alters cardiovascular
hemodynamics, and results in free radical generation. In turn,
a variety of deleterious processes such as endothelial dysfunc-
tion, inﬂammation, platelet aggregation, atherosclerosis, and
ﬁbrosis are triggered, predisposing individuals to adverse car-
diovascular events and likely renal damage. Independent of
obesity, OSA is associated with glomerular hyperﬁltration
and may be an independent predictor of proteinuria, a risk fac-
tor for CKD progression. OSA is also associated with hyper-
tension, another important risk factor for CKD progression,
particularly protein uric CKD [23].
Conclusions
OSA patients can be complicated with cardiac diseases, DM
and renal impairment through elevated resistin serum levels.
Recommendations
Effect of CPAP on resistin serum level must be evaluated in
these patients.
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